According to data ARS Pharmaceuticals originally planned to present at the 2020 Annual Meeting of the American Academy of Allergy, Asthma & Immunology (AAAAI) before its cancellation due to the situation with coronavirus disease 2019 (COVID-19), Neffy 1 mg has the potential to be the first intranasal epinephrine spray product to demonstrate bioequivalent exposure with more rapid absorption, as compared to epinephrine intramuscular injection (IM). These results were consistent across three landmark studies: EPI 03, EPI 04 and EPI 07. The data—which were presented through three abstracts that are now published in an online supplement to The Journal of Allergy and Clinical Immunology—indicate a needle-free alternative to epinephrine administration could be possible.
Neffy is an investigational intranasal epinephrine spray that may provide an easy-to-use, convenient and more reliable treatment for severe allergic reactions to food, medications and insect bites that could lead to life-threatening anaphylaxis.
Read more from AAAAI: EPINEPHRINE NASAL SPRAY DEMONSTRATES BIOEQUIVALENT EXPOSURE AND ABSORPTION RATE COMPARED TO EPINEPHRINE INJECTORS